Posted by Michael Wonder on 03 May 2018
Herzuma (trastuzumab), a biosimilar for the treatment of breast cancer, now available in Europe
2 May 2018 - Herzuma is the third biosimilar to be marketed and distributed by the Mundipharma network in Europe, which is a testament to Mundipharma’s leadership and expertise in biosimilars.
The Mundipharma global network of independent associated companies today announced that Herzuma, biosimilar trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming months.
The Mundipharma network has exclusive distribution rights to Herzuma in the UK, Germany, Italy, Ireland, Belgium, Luxembourg and the Netherlands.
